Companies › JCR Pharmaceuticals
3 active drug programs in 6 registered trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pabinafusp Alfa (JR-141) Transferrin receptor binding agent | TFRC, TFR2 | Phase 3 | Mucopolysaccharidosis II | Dec 2026 |
| JR-446 Gene therapy for mucopolysaccharidosis type IIIB | – | Phase 1 | Mucopolysaccharidosis IIIB; Mucopolysaccharidosis III-B | Jun 2028 |
| JR-441 (posnafusp alfa) Recombinant N-acetyl-alpha-glucosaminidase (NAGLU) enzyme replacement therapy | NAGLU | Phase 1 | Mucopolysaccharidosis III-A | Oct 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03708965 | Pabinafusp Alfa (JR-141) | Phase 2 | Mucopolysaccharidosis II | Metabolic and endocrine | Dec 2026 |
| NCT04573023 | Pabinafusp Alfa (JR-141) | Phase 3 | Mucopolysaccharidosis II | Metabolic and endocrine | Oct 2027 |
| NCT07640984 | JR-446 | Phase 1 | Mucopolysaccharidosis IIIB | Metabolic and endocrine | Jun 2028 |
| NCT06095388 | JR-441 (posnafusp alfa) | Phase 1 | Mucopolysaccharidosis III-A | Metabolic and endocrine | Oct 2029 |
| NCT04348136 | Pabinafusp Alfa (JR-141) | Phase 2 | Mucopolysaccharidosis II | Metabolic and endocrine | Mar 2030 |
| NCT06488924 | JR-446 | Phase 1 | Mucopolysaccharidosis III-B | Metabolic and endocrine | Apr 2030 |
Ascletis Pharma (China) Laekna The United Bio-Technology (Hengqin) BrightGene Bio-Medical Technology Biomea Fusion
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.